Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
1,601
Views
1
CrossRef citations to date
0
Altmetric
Oncology

The relationship between cost and the recommendation, refusal, and discontinuation of treatment for chronic myeloid leukemia and multiple myeloma in Japan: a cross-sectional exploratory survey

Taro Munakataa Market Access, AbbVie GK, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-8673-0412
ORCID Icon,
Yutaka Handab Medical, AbbVie GK, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-7800-3258
ORCID Icon,
Toru Mizunob Medical, AbbVie GK, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0001-8811-662X
ORCID Icon,
Nobuko Tomiuchic Medical Solutions, INTAGE Healthcare Inc., Tokyo, JapanORCID Iconhttps://orcid.org/0000-0001-8708-8882
ORCID Icon,
Michael LoPrestid Health Economics and Outcomes Research, INTAGE Healthcare Inc., Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2389-8218
ORCID Icon &
Junichi Shimizub Medical, AbbVie GK, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0001-9078-0968
ORCID Icon
Pages 552-560 | Received 26 Jan 2022, Accepted 04 Apr 2022, Published online: 02 May 2022

References

  • Center for Cancer Control and Information Services, National Cancer Center. Cancer statistics in Japan. Tokyo: Center for Cancer Control and Information Services, National Cancer Center; 2018.
  • Center for Cancer Control and Information Services, National Cancer Center. Cancer statistics in Japan. Tokyo: Center for Cancer Control and Information Services, National Cancer Center; 2013.
  • INTAGE Healthcare. DI track. Tokyo: INTAGE Healthcare Inc.; 2019.
  • IQVIA. IQVIA pharmaceutical market statistics sales data period: 1989–2018 (in Japanese). Tokyo: IQVIA; 2019.
  • IQVIA. IQVIA pharmaceutical market statistics sales data period: January – December, 2019 (in Japanese). Tokyo: IQVIA; 2020.
  • Economic and Social Research Institute. Annual report on national accounts of 2019 (in Japanese). Tokyo: Economic and Social Research Institute; 2019.
  • Ministry of Health, Labor, and Welfare. Overview of medical service regime in Japan. Tokyo: Ministry of Health, Labor, and Welfare; 2021.
  • Ministry of Health, Labor, and Welfare. Overview for those using high cost medical care (in Japanese). Tokyo: Ministry of Health, Labor, and Welfare; 2018.
  • Ministry of Health, Labor, and Welfare. Survey on the salary structure – report summary of year 2017 (in Japanese). Tokyo: Ministry of Health, Labor, and Welfare; 2017.
  • Koinuma N. Proposal for the breakdown of increased cancer healthcare cost and its improvement. Jpn J Clin Oncol. 2013;43(4):552–356.
  • INTAGE Healthcare Inc. Patient mindscape (APM) survey. Tokyo: INTAGE Healthcare Inc.; 2019.
  • Shiroiwa T, Tsutani K. Research on inclusion of health economics in treatment guidelines (in Japanese). Tokyo (Japan): Health Labor Sciences Research Grant, Ministry of Health, Labor and Welfare; 2016.
  • Bolt T, Mahlich J, Nakamura Y, et al. Hematologists' preferences for first-line therapy characteristics for multiple myeloma in Japan: attribute rating and discrete choice experiment. Clin Ther. 2018;40(2):296–308.
  • Arikian SR, Milentijevic D, Binder G, et al. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin. 2015;31(6):1105–1115.
  • Laudicella M, Walsh B, Burns E, et al. Cost of care for cancer patients in England: evidence from population-based patient-level data. Br J Cancer. 2016;114(11):1286–1292.
  • Serra-Arbeloa P, Rabines-Juarez AO, Alvarez-Ruiz MS, et al. Cost of cutaneous melanoma by tumor stage: a descriptive analysis. Actas Dermosifiliogr. 2017;108(3):229–236.
  • Sun L, Legood R, Dos-Santos-Silva I, et al. Global treatment costs of breast cancer by stage: a systematic review. PLoS One. 2018;13(11):e0207993.
  • Ward RL, Laaksonen MA, van Gool K, et al. Cost of cancer care for patients undergoing chemotherapy: the elements of cancer care study. Asia Pac J Clin Oncol. 2015;11(2):178–186.
  • Dranitsaris G, Zhu X, Adunlin G, et al. Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs. Expert Rev Pharmacoecon Outcomes Res. 2018;18(4):351–357.
  • Kawamura M, Takao H, Okumura M, et al. Review of colorectal cancer cases based on their route of detection (in Japanese). Ningen Dock. 2015;30:616–622.
  • KEGG Medicus. Dexamethasone listing. Kyoto: KEGG Medicus.
  • KEGG Medicus. Lenalidomide listing. Kyoto: KEGG Medicus.
  • KEGG Medicus. Daratumumab listing. Kyoto: KEGG Medicus.
  • KEGG Medicus. Dasatinib Listing. Kyoto: KEGG Medicus.
  • Bristol Meyers Squibb KK. Sprycel 20mg/50mg usage survey report. Tokyo: Bristol Meyers Squibb KK; 2015.
  • Ministry of Health, Labor, and Welfare. 2018 Physician survey report. Tokyo: Ministry of Health, Labor, and Welfare; 2018.
  • Ministry of Health, Labor, and Welfare. 2018 Survey of medical institutions report. Tokyo: Ministry of Health, Labor, and Welfare; 2018.
  • Ministry of Health, Labor, and Welfare. Cancer base hospital listing. Tokyo: Ministry of Health, Labor, and Welfare; 2018.
  • Usui N. JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol. 2017;106(5):591–611.
  • CancerMPact®. 2020 [cited 2020 Apr 24]. Available from: Cerner EnvizaSM/Synix Inc.: synix.co.jp/cancermpact (Unauthorized reproduction prohibited).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.